BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang M, Olaoba OT, Zhang C, Kimchi ET, Staveley-o’carroll KF, Li G. Cancer Immunotherapy and Delivery System: An Update. Pharmaceutics 2022;14:1630. [DOI: 10.3390/pharmaceutics14081630] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Desai N, Hasan U, K J, Mani R, Chauhan M, Basu SM, Giri J. Biomaterial-based Platforms for Modulating Immune Components against Cancer and Cancer Stem Cells. Acta Biomater 2023:S1742-7061(23)00130-7. [PMID: 36907233 DOI: 10.1016/j.actbio.2023.03.004] [Reference Citation Analysis]
2 Kang Y, Li S. Nanomaterials: Breaking through the bottleneck of tumor immunotherapy. Int J Biol Macromol 2023;230:123159. [PMID: 36610572 DOI: 10.1016/j.ijbiomac.2023.123159] [Reference Citation Analysis]
3 Fang L, Tian W, Zhang C, Wang X, Li W, Zhang Q, Zhang Y, Zheng J. Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma. Pharmacol Res 2023;189:106701. [PMID: 36796464 DOI: 10.1016/j.phrs.2023.106701] [Reference Citation Analysis]
4 Olaoba OT, Ayinde KS, Lateef OM, Akintubosun MO, Lawal KA, Adelusi TI. Is the new angel better than the old devil? Challenges and opportunities in CD47- SIRPα-based cancer therapy. Crit Rev Oncol Hematol 2023;184:103939. [PMID: 36774991 DOI: 10.1016/j.critrevonc.2023.103939] [Reference Citation Analysis]
5 Ruff SM, Shannon AH, Beane JD, Pawlik TM. Highlighting novel targets in immunotherapy for liver cancer. Expert Rev Gastroenterol Hepatol 2022;16:1029-41. [PMID: 36404729 DOI: 10.1080/17474124.2022.2150841] [Reference Citation Analysis]
6 Bukhari I, Zhang Y, Thorne RF, Mi Y. Editorial: Complexity of tumor microenvironment: A major culprit in cancer development. Front Endocrinol 2022;13:1059885. [DOI: 10.3389/fendo.2022.1059885] [Reference Citation Analysis]